The Global COVID-19 impact on, consumer behavior/patient expectations, healthcare, and pharmacy workforce was noticeable.
The importance of pharmacy technicians in healthcare delivery pre-COVID-19, during crisis, and post-COVID-19 is crucial for the healthcare and patient services.
Pharmacy technicians from different work settings, community, hospital and pharmacy technicians’ association share their experiences with the public

Moderators:
Vijay Sarma, VP Pharmacy Marketing, McCann Health, Canada
Teri-Lynne Fogarty, Lecturer/ Coordinator of Pharmacy technician programme, Nelson Mandela University, South Africa

Speakers:
Isnarti Abu Aman, Pharmacy Technician Executive, Khoo Teck Puat Hospital, Singapore

Lorah Hickman, Senior Pharmacy Technician for Workforce and Development
Alfred Hospital, Australia

Birgitte Jeanette Andersen, Pharmaceutical consultant, Denmark

Mike Johnston, CEO, National Pharmacy Technician Association, USA

The world’s pharmacy team is fighting COVID-19 in a variety of ways. This webinar will host stakeholders working in various pharmacy sectors and from different geographical regions to share examples and draw on what we can learn in our pursuit of resilience. Research-driven findings will be shared that may aid in developing and advancing resilience within ourselves, for our patients, colleagues and the systems we are a part in our ability to tackle very challenging times. This event is delivered by FIP in collaboration with GRiT – Global Resilience Team, Led by: Dr Karen Whitfield.

The webinar aims to:
- Introduce participants to GRiT - Global Resilience Team ethos; a collaborative team passionate for raising awareness of the importance of developing resilience in our workforce.
- Showcase global perspectives from research and practice related to resilience in pharmacy.
- Share experiences in developing relevant and practical material to build into pharmacy curricula.

Moderator:
- Prof. Zubin Austin, Koffler Research Chair in Management, Leslie Dan Faculty of Pharmacy and Institute for Health Policy, Management, and Evaluation - Faculty of Medicine at the University of Toronto - Canada

Event Chair:
- Dr Catriona Bradley, Executive Director, The Irish Institute of Pharmacy - Ireland

Panellists:
- Dr Karen Whitfield, Associate Professor, School of Pharmacy, The University of Queensland - Australia
- Dr Sarah Wills, Senior Lecturer, The University of Manchester - UK
- Dr Dalia Bajis, Assistant Professor, Mohammed Al-Mana College for Medical Sciences - Saudi Arabia
- Dr Kyle Wilby, Associate Dean (Undergraduate) and Associate Professor, School of Pharmacy, University of Otago - New Zealand
- Dr Vibhuti Arya, Global Lead, Equity and Equality, International Pharmaceutical Federation (FIP) - USA
- Elizabeth Shekalaghe, Registrar /CEO, Pharmacy Council Tanzania - Tanzania
- Catherine Duggan, CEO, International Pharmaceutical Federation (FIP) - The Netherlands

Aim
To describe an evidence-based approach to self-care of mild COVID-19 symptoms

Learning Objectives:
• Describe approaches for preventing the spread of COVID-19
• List symptoms of COVID-19 – similarities and differences to influenza;
• Identify myths associated with self-care of COVID-19.
• Describe how mild symptoms such as fever and pain should be managed;
• Discuss when to refer more serious cases (escalating care in COVID-19).

Target audience – all those involved in the primary health care response to the coronavirus pandemic

Programme:
1. Welcome – Moderator Gonçalo Sousa Pinto, FIP Lead for Practice Development and Transformation

2. COVID-19: preventing its spread and understanding its symptoms – Jaime Acosta-Gómez, Community Pharmacist and Pharmacy Owner, Spain

3. Dispelling myths about self-care treatments of COVID-19 – Christopher John, FIP Lead for Data and Intelligence

4. How to manage mild symptoms – self-care case study. Lars-Åke Söderlund, President FIP Community Pharmacy Section

5. Panel Discussion – questions and answers – All speakers

The COVID-19 pandemic has created an urgent need for diagnostic testing of patients and populations. In response, a multitude of COVID-19 tests are available to use from many different manufacturers and organisations. FIP has created a counselling information guide to assist practising pharmacists around the world in talking to patients who have questions concerning COVID-19 tests. This joint FIP-ASHP online event will present the newly developed guidance on Evaluation of Diagnostic Testing & Methods, as well as tools for pharmacists developed by the American Society of Health-System Pharmacists (ASHP). Panellists will discuss issues about care and how to manage the risks with evidence is the focus.

Moderator:
Zuzana Kusynova, Lead for Policy, Practice and Compliance, FIP, Netherlands

Panellist:
Mary Ann Kliethermes, Director, Medication Safety and Quality, American Society of Health-System Pharmacists (ASHP), USA

Catherine Duggan, CEO, FIP, Netherlands

Julien Fonsart, Senior specialist in laboratory medicine pharmacist, Hôpital Lariboisière, Université de Paris, France

Ally Dering-Anderson, Clinical Associate Professor in the Department of Pharmacy Practice & Science, University of Nebraska College of Pharmacy, USA

Margaret Underwood, Pharmacy student & FIP Intern, FIP, USA

Jasminka N Sarunac, Lead Pharmacist Investigational drugs/Clinical trial, Pharmacoepidemiologist, John Hunter Hospital, Australia

Se generó, durante esta pandemia, diversos tipos de evidencia respecto a los tratamientos para la Covid-19 pero aún así, el farmacéutico se enfrenta a la necesidad de tomar decisiones en ausencia de evidencia científica. Para apoyar la toma de decisiones, se compartirán los caminos emprendidos en el Hospital G. Marañón para la selección y protocolización del tratamiento para Covid-19 mostrando las herramientas utilizadas. La segunda parte será dedicada a los sistemas de farmacovigilancia (FV) sostenibles. La FV no es una actividad de lujo sino que es la base del uso seguro de medicamentos. Involucrar al paciente. Uso off-label de medicamentos.

1. Identificar los principales retos en la selección y protocolización de los tratamientos para Covid-19 en un contexto de falta de evidencia científica.
2. Analizar rol de las agencias reguladoras, la Comisión de Farmacia y Terapéutica del hospital, el grupo de expertos Covid-19 y grupo PROA del hospital y el farmacéutico en enfermedades infecciosas.
3. Compartir la experiencia en el abordaje de la selección y protocolización del tratamiento para Covid-19.
4. Discutir estrategias para organizar sistemas sostenibles para la gestión de riesgos de productos farmacéuticos y dispositivos médicos en la farmacia hospitalaria post-Covid.

Moderadora:
Nora Gerpe, Química Farmacéutica Asociación de Química y Farmacia del Uruguay-Uruguay

Panelistas:
Carmen Rodriguez, Farmacéutica Hospitalaria Hospital General Universitario Gregorio Marañón - España
Lucila Castro Pastrana, Full Professor Universidad de las Américas, Puebla - México

Tras la irrupción de la infección respiratoria por el nuevo coronavirus SARS-CoV-2, el desarrollo de vacunas capaces de proporcionar protección individual y poblacional frente a este virus se presenta como uno de los pilares fundamentales para controlar su expansión. Por otro lado, entre los numerosos efectos de la pandemia actual, conviene destacar los relacionados con la interrupción de los servicios básicos de salud, entre ellos, los programas de vacunación que están sufriendo importantes caídas y demoras en la mayoría de los países. En esta conferencia se abordarán las diferentes vacunas que se están en progreso para COVID-19, las tecnologías utilizadas y los adelantos en su desarrollo, así como la importancia de reestablecer y mantener los sistemas de inmunización.

Objetivos:
• Conocer las nuevas vacunas que están en desarrollado en el mundo para COVID-19.
• Describir el avance del proceso de desarrollo de las diferentes vacunas para COVID-19.
• Reconocer la importancia de la vacunación en el contexto de la pandemia.

Moderator: Nai-Hwa Mei
Panellists: Anasemon Aioub, Edurne Fdez. de Gamarra Martínez

The presentation is available here. Read the Covid-19 Special Collection by Pharmacy Education here. More on Pharmacy Education. 

The presentation is available here.

OBJETIVOS
• Conocer las áreas de impacto del COVID-19 en el sistema de salud.
• Describir los efectos del COVID-19 en la salud mental de los farmacéuticos y otros trabajadores de salud.
• Desarrollar un enfoque ampliado de los resultados generados por la pandemia que sirvan para el diseño de estrategias futuras de resiliencia.

The presentation is available here.

The presentation is available here.

Presentation is available here.

Presentation is available here.

The presentation is available here.

The presentation is available here.

Presentation is available here.

Presentation is available here

Presentation is available here